Yuka Hirakawa, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Basement Membrane | 1 | 2020 | 348 | 0.670 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2024 | 975 | 0.620 |
Why?
|
| Epidermis | 1 | 2020 | 529 | 0.580 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2024 | 1765 | 0.550 |
Why?
|
| Aortic Diseases | 1 | 2022 | 736 | 0.550 |
Why?
|
| Thromboembolism | 1 | 2022 | 1016 | 0.520 |
Why?
|
| Non-Fibrillar Collagens | 1 | 2015 | 25 | 0.510 |
Why?
|
| Ultraviolet Rays | 1 | 2020 | 1078 | 0.510 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 2015 | 115 | 0.470 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 1293 | 0.380 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2024 | 4024 | 0.380 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2015 | 240 | 0.370 |
Why?
|
| Autoantigens | 1 | 2015 | 877 | 0.360 |
Why?
|
| Membrane Glycoproteins | 1 | 2020 | 3731 | 0.330 |
Why?
|
| Heart Diseases | 1 | 2022 | 2809 | 0.330 |
Why?
|
| Carcinoma | 1 | 2021 | 2334 | 0.330 |
Why?
|
| Myositis | 2 | 2023 | 269 | 0.310 |
Why?
|
| Thrombosis | 1 | 2022 | 3052 | 0.310 |
Why?
|
| Skin Neoplasms | 2 | 2024 | 5797 | 0.290 |
Why?
|
| Autoantibodies | 1 | 2015 | 2119 | 0.270 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 4546 | 0.210 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 11891 | 0.190 |
Why?
|
| Mesenteric Veins | 1 | 2021 | 83 | 0.190 |
Why?
|
| Collagen Type IV | 1 | 2020 | 127 | 0.180 |
Why?
|
| Trismus | 1 | 2019 | 32 | 0.170 |
Why?
|
| Laminin | 1 | 2020 | 405 | 0.160 |
Why?
|
| Facial Muscles | 1 | 2019 | 159 | 0.160 |
Why?
|
| Fasciitis | 1 | 2019 | 66 | 0.160 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2020 | 462 | 0.150 |
Why?
|
| Portal Vein | 1 | 2021 | 429 | 0.150 |
Why?
|
| Organ Culture Techniques | 1 | 2020 | 796 | 0.150 |
Why?
|
| Still's Disease, Adult-Onset | 1 | 2017 | 22 | 0.150 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2020 | 633 | 0.140 |
Why?
|
| Bacteremia | 1 | 2023 | 979 | 0.140 |
Why?
|
| Asymptomatic Diseases | 1 | 2020 | 582 | 0.140 |
Why?
|
| Ferritins | 1 | 2017 | 598 | 0.120 |
Why?
|
| Aorta | 1 | 2022 | 2042 | 0.120 |
Why?
|
| Pancreas | 1 | 2021 | 1677 | 0.120 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2017 | 266 | 0.110 |
Why?
|
| Pain, Postoperative | 1 | 2023 | 1718 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 3762 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2022 | 4896 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2020 | 12762 | 0.060 |
Why?
|
| Male | 6 | 2024 | 359413 | 0.060 |
Why?
|
| Humans | 11 | 2024 | 760261 | 0.050 |
Why?
|
| Erythema | 1 | 2023 | 262 | 0.050 |
Why?
|
| Cellulitis | 1 | 2023 | 208 | 0.050 |
Why?
|
| Aged | 4 | 2024 | 168995 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2023 | 555 | 0.050 |
Why?
|
| Middle Aged | 3 | 2024 | 220175 | 0.040 |
Why?
|
| Morphine | 1 | 2023 | 656 | 0.040 |
Why?
|
| HIV Infections | 1 | 2023 | 17159 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2023 | 6830 | 0.030 |
Why?
|
| Fever | 1 | 2019 | 1618 | 0.020 |
Why?
|
| Female | 3 | 2024 | 391011 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 20484 | 0.020 |
Why?
|
| Prevalence | 1 | 2023 | 15687 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2023 | 80301 | 0.010 |
Why?
|
| Prognosis | 1 | 2023 | 29636 | 0.010 |
Why?
|
| United States | 1 | 2023 | 72363 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 58947 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 36247 | 0.010 |
Why?
|
| Adult | 1 | 2023 | 219847 | 0.000 |
Why?
|